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Host-directed therapies (HDTs) are emerging as a potential valid support in the treatment
of drug-resistant tuberculosis (TB). Following our recent report indicating that genetic
and pharmacological inhibition of transglutaminase 2 (TG2) restricts Mycobacterium
tuberculosis (Mtb) replication in macrophages, we aimed to investigate the potentials
of the TG2 inhibitors cystamine and cysteamine as HDTs against TB. We showed that
both cysteamine and cystamine restrictedMtb replication in infected macrophages when
provided at equimolar concentrations and did not exert any antibacterial activity when
administered directly on Mtb cultures. Interestingly, infection of differentiated THP-1
mRFP-GFP-LC3B cells followed by the determination of the autophagic intermediates pH
distribution (AIPD) showed that cystamine inhibited the autophagic flux while restricting
Mtb replication. Moreover, both cystamine and cysteamine had a similar antimicrobial
activity in primary macrophages infected with a panel of Mtb clinical strains belonging
to different phylogeographic lineages. Evaluation of cysteamine and cystamine activity in
the human ex vivo model of granuloma-like structures (GLS) further confirmed the ability
of these drugs to restrictMtb replication and to reduce the size of GLS. The antimicrobial
activity of the TG2 inhibitors synergized with a second-line anti-TB drug as amikacin in
humanmonocyte-derived macrophages and in the GLSmodel. Overall, the results of this
study support the potential usefulness of the TG2-inhibitors cysteamine and cystamine
as HDTs against TB.
Keywords: tuberculosis, transglutaminase 2, host-directed therapy, Mycobacterium tuberculosis, macrophage,
MDR-TB
INTRODUCTION
Tuberculosis (TB) is a leading cause of death worldwide with 10 million new TB cases and 1.6
million deaths in 2017 alone (1). The emergence and spread of Mycobacterium tuberculosis (Mtb)
strains resistant to the two most common drugs isoniazid and rifampicin (multidrug-resistant
Mtb, MDR-TB) are a cause of major concern. Among the half million cases of MDR-TB
estimated in 2017, 8.5% are expected to have a pattern of extensively drug resistant-TB (XDR-TB),
defined as the additional non-susceptibility to fluoroquinolones and an injectable drug (1). Drug
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regimens for MDR-TB patients are much more complex and
toxic compared to those commonly administered to patients with
drug-susceptible TB and consist in the combined administration
of at least four drugs for up to 20 months (2, 3). Despite the
introduction of new drugs, therapeutic regimens of MDR-TB
and XDR-TB patients show poor success rates that rarely exceed
50% in high-burden countries (4). Moreover, these regimens are
very expensive; combining direct and indirect costs, in EU states
and the US, the average cost for an MDR-TB patient is five to
six times higher than a drug-susceptible patient and increases
up to 20 times for XDR-TB (2, 5). These high costs associated
with the treatment of drug-resistant TB pose a major burden
to many countries, with relevant health, social, and economic
consequences (2).
There is an urgent need of improved treatment options for
TB, and the introduction of the new drugs delamanid and
bedaquiline, while widening the therapeutic options, has already
led to the emergence of Mtb strains resistant to these drugs (6),
frustrating the hopes of scientists, public health authorities, and
patients. In the last few years, also thanks to new insights in
TB pathogenesis, several host-directed therapies (HDTs) have
been proposed as adjunct therapy against TB and primarily
against the drug-resistant forms that do not respond to the
available treatments (7–9). Some of these HDTs are based on the
repurposing of old drugs which have already shown a good safety
record in previous clinical trials (7, 8), as is the case formetformin
(10), statins (11), and other drugs (12). These treatments may
enhance the host antimicrobial defenses or provide beneficial
effects by interfering with the mechanisms exploited by the
pathogen to persist in host tissues or by lessening inflammation
and reducing tissue damage. These beneficial effects of HDTs
can synergize with the anti-TB regimens, resulting in improved
clinical outcomes and reduced risk for emergence of drug
resistance, and may lead to shorter anti-TB regimens.
Transglutaminase 2 (TG2) is a pleiotropic enzyme belonging
to the transglutaminase family involved in several important
cellular processes including cell death/survival and autophagy
(13–15).We have recently shown that genetic or pharmacological
inactivation of TG2 enhances the anti-mycobacterial properties
of Mtb-infected macrophages, which intriguingly correlate with
reduced cell death and impairment of the LC3/autophagy
homeostasis (16). Interestingly, two TG2 inhibitors, cystamine
and cysteamine, have already been tested in clinical trials and
showed a good safety record (17, 18). Briefly, cystamine inhibits
most of the extracellular transglutaminases, while its reduced
form cysteamine can more efficiently reach the cytoplasm and
inhibit transglutaminase intracellular activities (19). In this study,
we aimed to investigate in relevant in vitro and ex vivomodels of
human Mtb infection whether these two TG2 inhibitors act as
HDTs against TB.
RESULTS
Cysteamine and Cystamine Act as a
Host-Directed Therapy Against Mtb
We have recently shown that treatment of murine and human
primary macrophages with cystamine, a TG2 inhibitor, enhances
the anti-tuberculosis activity of macrophages (16). The reduced
form of cystamine, cysteamine, is an orphan drug also well-
known as TG2 inhibitor already tested in clinical studies to treat
non-infectious diseases (18). To investigate whether cysteamine
had an anti-microbial activity against Mtb in macrophages,
THP-1 monocyte-derived macrophages were infected with Mtb
H37Rv and then treated with cystamine and cysteamine at
concentrations compatible to those achieved in vivo (16). As
shown in Figure 1A, treatment with cysteamine resulted in a
dose-dependent reduction of intracellular bacteria that reached a
similar activity with cystamine when administered at equimolar
concentrations (400µM cystamine, 800µM cysteamine). At
these concentrations, treatment with cystamine or cysteamine
did not reduce macrophage cell viability (as assessed by
measuring lactate dehydrogenase, data not shown) nor inhibit
Mtb H37Rv viability in axenic culture (Figure 1B), similar
to what was previously shown for cystine or cysteine (20).
Moreover, the combined use of isoniazid with these two drugs,
at concentrations previously used in macrophages, provided only
a slight delay in the emergence of drug-resistant bacteria. Besides,
these treatments did not result in the sterilization or strong
inhibition of the persistent population (Figure 1B), as previously
observed with other molecules with a free-thiol group [though
when administered at higher concentration as is the case of N-
acetylcysteine (NAC) at 4mM; Figure 1B] (20). Taken together
these results indicate that cystamine and cysteamine, at the
concentrations shown to inhibitMtb replication in macrophages,
do not exert any direct antimicrobial effect onMtb.
Cystamine Restricts Mtb Replication in
Macrophages While Inhibiting Autophagy
We previously showed that genetic inactivation of TG2 inmurine
macrophages results in the impairment of the LC3/autophagy
homeostasis, which nevertheless correlates with the restriction
of Mtb intracellular replication (16). To further investigate the
impact of the two TG2 inhibitors cystamine and cysteamine
on autophagy, we quantitatively evaluated the autophagic
flux by confocal pH-imaging of the autophagic intermediates
on THP-1 cells transfected with mRFP-GFP-LC3B (21). The
number and pH of autophagic intermediates are expressed
by autophagic intermediates pH distribution (AIPD), the pH
distribution of the number of autophagic intermediates per
cell. AIPD shape and amplitude are sensitive to alterations in
the autophagy pathway induced by drugs or environmental
states and allow a quantitative estimation of autophagic flux
by retrieving the concentrations of autophagic intermediates.
Briefly, the total area of the AIPD corresponds to the total
number of autophagic intermediates. An increase of high FG/FR
organelles indicates an increase of autophagomes. Formation of
autolysosomes (autophagosome–lysosome fusion) is indicated
by a shift of AIPD toward low FG/FR values, caused by
a decrease of the pH of autophagic intermediates. Thus,
this assay is not only a marker of autophagy activation but
also allows for an accurate estimation of the autophagic
flux (21).
We first assessed the suitability of the assay following
infection with the virulent Mtb H37Rv and the attenuated
strain Mycobacterium bovis BCG, which is unable to inhibit
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FIGURE 1 | Cystamine and cysteamine exert anti-mycobacterial activity only in infected macrophages. (A) THP-1 cells were infected with Mtb at MOI 1:10 and
treated with the drugs starting at 4 h p.i. until harvesting of intracellular CFU at 2 days p.i. Cystamine (400µM) or cysteamine at different concentrations (from 250 to
800µM) and isoniazid at MIC concentration were administered to infected macrophages 4 h p.i. The graph shows intracellular CFU at 2 days p.i. for the untreated and
treated THP-1. Data were analyzed by one-way ANOVA followed by Dunnett’s multiple-comparisons test (***p < 0.005, compared with Mtb H37Rv no treatment). (B)
Viability of Mtb treated with INH (7.3µM, 20 times the MIC), cystamine (400µM) or cysteamine (800µM), NAC (4.0mM), and combination of these with INH. The
experiments, in which the combinations are shown, were performed using the same concentrations of drugs as the individual treatments. Aliquots were taken at
indicated times and plated to determine CFU. Average with SD is plotted (n = 1). Values are expressed as a mean of three independent experiments. Data were
analyzed by one-way ANOVA with Dunnett’s multiple-comparisons test against Mtb H37Rv untreated (***p < 0.005, ****p < 0.001).
autophagy and is readily degraded by macrophages (22).
Infection with Mtb and BCG expressing the Ds-Red Cherry
fluorescent protein, followed by the confocal analysis of
autophagic intermediates (21), allows distinguishing autophagic
activation and flux in infected and non-infected cells (Figure 2).
A visual inspection of the AIPDs reveals that, in BCG-infected
cells (Figure 2A), not only autophagosomes are formed at
2 h post-infection (p.i.) (increase of high FG/FR shoulder)
but also autolysosomes are forming (simultaneous shift of
AIPD toward low FG/FR values). The observed decrease of
the total number of intermediates during the time course
indicates an increased autophagic flux accompanied by a
gradual autophagy inactivation (intermediates almost disappear
at 24 h). Therefore, this indicates that the overall duration of
the autophagy process in THP-1 cells infected with BCG is
≈24 h (Figures 2A–C).
Infection with virulent Mtb (Figures 2B–D) activates
autophagy, though the AIPD shift toward acidic pH is less
pronounced compared to BCG-infected cells and is accompanied
by an increase of the neutral organelles. In contrast with the
correspondent non-infected cells, the peak of autophagosomes
(high FG/FR values) is higher than the peak of autolysosomes
(low FG/FR values; Figure 2B). This change in the shape of
the distribution indicates Mtb inhibition of the autophagic flux
following infection by preventing intermediate acidification,
in line with previous findings (22–24). Another important
difference between BCG- and Mtb-infected macrophages is
that AIPD in the latter does not undergo important changes in
shape over the same 24-h time course, indicating that cells keep
autophagy activated even at 24 h p.i. These results underscore
the usefulness of the quantitative analysis of AIPD to monitor
authophagy in macrophages infected with Mtb. Of note, we also
observed autophagic flux induction in non-infectedmacrophages
(in BCG- and Mtb-infected cells), probably resulting from the
cytokines released by infected cells (24, 25) that can act in
paracrine mode.
To investigate the impact of the TG2 inhibitors on autophagy,
THP-1 mRFP-GFP-LC3B cells were infected with Mtb H37Rv
Ds-Red Cherry and then treated with rapamycin, cystamine,
and cysteamine immediately after infection, and AIPD was
measured at 24 h later (Figure 3). As expected, treatment with
rapamycin readily induced an increase in autophagic flux;
AIPD displays an acidification of intermediates (Figure 3A)
with respect to untreatedMtb-infectedmacrophages (Figure 3B).
Conversely, treatment with cysteamine resulted in a decrease
of autophagosome acidification (Figures 3A,B), thus indicating
a partial inhibition of the autophagic flux at the level of
autophagosome maturation. To quantify the extent of the
activation or inhibition of the autophagic flux, we reported in
Figure 3C the ratio A/B between the AIPD area at the left (A)
and at the right (B) of a fixed threshold value (FG/FR = 0.55).
An increase in A/B value corresponds to an increase in the
autophagic flux. These findings are in full agreement with the
impairment of late autophagic stages reported in TG2 knockout
mice (26). Taken together, these results indicate that treatment
with cystamine, and to a lesser extent cysteamine, of THP-1
mRFP-GFP-LC3B cells infected withMtb results in the inhibition
of the autophagic flux.
Pharmacological Inhibition of TG2
Restricts Mtb Replication of Modern and
Ancient Mtb Clinical Isolates
Mtb strains belonging to different phylogeographic lineages
show different pathogenetic properties, with implications in
terms of virulence, extent of disease, transmission, and epidemic
potentials (25, 27–29).Mtb strains belonging to modern lineages
showed enhanced virulence compared with strains of the
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FIGURE 2 | Autophagic flux is altered in virulent Mtb H37Rv strain compared to M. bovis BCG. THP-1 RFP-LC3-GFP cells infected with M. bovis BCG Ds-Red
Cherry at MOI 5:1 (A) and with virulent Mtb H37Rv Ds-Red Cherry at MOI 1:1 (B). Quantitative assessment of autophagic flux during the time interval lasting 24 h
post-infection. Reported in the graphs are the number and pH of autophagic intermediates expressed by AIPD, the pH distribution of the number of autophagic
intermediates per cell. AIPD shape and amplitude are sensitive to alterations in the autophagy pathway induced by drugs or environmental states and allow a
quantitative estimation of autophagic flux by retrieving the concentrations of autophagic intermediates. An increase of high FG/FR organelles indicates an increase of
autophagomes. A shift of AIPD toward low FG/FR values indicates that the pH of autophagic intermediates is shifting to acidic values and autolysosomes formation.
(C,D) Bar graphs on the trend of autophagy during infection of M. bovis BCG and Mtb, respectively, expressed as ratios FG/FR (A/B) between the AIPD area of a fixed
threshold value. Data were analyzed by two-way ANOVA with Bonferroni’s multiple-comparisons test (*p < 0.05).
ancient lineages, and recent data from our group indicate a
different ability to induce and evade autophagy by modern
vs. ancient strains (25). To investigate whether treatment with
TG2 inhibitors could restrict the intracellular replication of
Mtb belonging to different lineages, THP-1 cells were infected
with Mtb clinical isolates of the modern Euro-American (H3
clade) and East Asian (Beijing) lineages and of the ancient
lineage EAI (EAI_MAN). As shown in Figure 4, treatment with
cysteamine and cystamine were equally effective in restricting
Mtb replication of strains of different clades, with a decrease
over the untreated control that ranged between 35 and 50%
(Figure 4B). Interestingly, we show a 50% decrease in THP-1 cells
infected with the Beijing Mtb strain. These results indicate that
cysteamine and cystamine promote an antimicrobial activity in
macrophages effective against clinical isolates representative of
theMtb genetic diversity at global level.
Cystamine Synergizes With Capreomycin
in Restricting Mtb Replication in Primary
Human Monocyte-Derived Macrophages
HDTs against TB have the potential to synergize with
antimicrobial drugs to enhance the efficacy of therapy. This
is of utmost importance during treatment of drug-resistant
TB, which relies on antibiotics that are less powerful than the
first-line drugs (9). As a proof of concept, to investigate the
potential usefulness of the TG2-inhibitors under study, human
monocyte-derived macrophages (hMDM) were infected with
Mtb and then treated with cystamine, cysteamine alone, or in
combination with the second-line anti-TB drug capreomycin.
As shown in Figure 5, cystamine reduced Mtb replication in
macrophages at a higher level compared to rapamycin (16) and
similarly to capreomycin when these drugs were administered
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FIGURE 3 | Cystamine and cysteamine block autophagy in Mtb-infected macrophages. Representative confocal laser scanning images of THP-1 RFP-LC3-GFP
infected with Mtb H37Rv Ds-Red at MOI 1:1. At 4 h p.i., cystamine (400µM), cysteamine (800µM), or rapamycin (1mM) was added, and the images were acquired at
24 h p.i. The images represent the merge of the green and the red channels. Autophagic intermediates pH distribution (average of n = 80 cells) for the same
treatments is reported along the correspondent representative images. (C) Histogram of the ratios FG/FR (A/B) between the AIPD area at the left (A) and at the right
(B) of a fixed threshold value. An increase in A/B value corresponds to an increase in the autophagic flux. Data were analyzed by two-way ANOVA with Bonferroni’s
multiple-comparisons test (***p < 0.005).
at 4 h p.i. and intracellular Mtb evaluated after 2 days of
infection. Interestingly, the combined use of cystamine and
capreomycin further reduced Mtb replication in macrophages,
indicating a synergistic effect of these drugs. A similar experiment
was repeated with amikacin, an aminoglycoside included in
group C of drugs endorsed for use in longer MDR-TB
regimens (30). As shown in Figure 5B, in hMDM, amikacin
significantly reduced Mtb intracellular growth even more than
the reduction generated by capreomycin (capreomycin = −0.32
log colony-forming units (CFU)/106 cells; amikacin = −0.89
log CFU/106 cells). Remarkably, the combined use of amikacin
and cysteamine or cystamine further reduced Mtb replication
in hMDM, providing a decrease of −1.22 log CFU/106 cells
for combination with cystamine and −1.24 log CFU/106 cells
for cysteamine over untreated infected hMDM (Figure 5B).
Interestingly, the respective anti-Mtb activity of amikacin
and capreomycin was lower at day 7 p.i. compared to
what was observed at day 2 p.i. (Figure 5C); differently, the
combination of aminoglycosides, particularly amikacin, with
cystamine and cysteamine resulted in a persistent and highly
significant reduction of intracellular CFU (Figure 5C). Taken
together, these results indicate that cystamine and cysteamine
can synergize with amikacin to enhance anti-TB activity in
infected hMDM.
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FIGURE 4 | Evaluation of cystamine and cysteamine effects in macrophages infected with different Mtb strains belonging to different lineages. Differentiated THP-1
cells were infected with MTBC clinical strains belonging to different clades (H3, Beijing, EAI_MAN) (25) at MOI 1:1. At 4 h p.i., the cells were treated with cystamine
(400µM) and cysteamine (800µM), and at 2 days p.i., cells were lysed to measure intracellular CFU (A). Values are expressed as a mean of three independent
experiments. (B) To compare the activity of the two drugs, results are expressed as percentage of mean value of CFU in triplicate of treated vs. untreated strains in
panels. Data were analyzed by two-way ANOVA with Dunnett’s multiple-comparisons test against each strain with untreated condition (**p < 0.01, ****p < 0.001).
FIGURE 5 | Evaluation of the synergistic effect of cystamine and cysteamine with aminoglycosides in human primary monocyte-derived macrophages (hMDM). hMDM
were infected with Mtb H37Rv at MOI 1:1, and at 4 h p.i., we added different drugs: cystamine (400µM), cysteamine (800µM); the antibacterial drugs belonging to
the aminoglycosides class capreomycin (4µg/ml, A) and amikacin (1µg/ml, B) and the combination of the aminoglycosides with cystamine and cysteamine. Two days
after infection, cells were lysed to assess intracellular CFU, and results are shown as log CFU/106 cells. (C) To measure the long-term effect in this in vitro model of
Mtb infection, hMDM were maintained up to 7 days p.i., and CFU were determined. Values are expressed as a mean of three independent experiments. Data were
analyzed by one-way ANOVA followed by Dunnett’s multiple-comparisons test (*p < 0.05, **p < 0.001, ***p < 0.005, ****p < 0.001 compared with Mtb H37Rv no
treatment). To measure the synergistic effect of cystamine and cysteamine in combination with capreomycin or amikacin in prolonged treatment, we compared groups
treated with antibiotic alone with those receiving the same antibiotic in combination with cysteamine or cystamine (**p < 0.01, ***p < 0.005 for amikacin treatments;
*p < 0.05, ***p < 0.001 for capreomycin treatment). Data obtained from single independent infections are reported in Supplementary Figure 1.
Cysteamine and Cystamine Are Active
Against Mtb in the Human ex vivo Model of
Granuloma-Like Structures
Infection of human peripheral blood monocyte cells (PBMCs)
with Mtb results in the formation of granuloma-like structures
(GLS) that are emerging as a valuable ex vivo model of TB
(31, 32). To investigate the activity of these HDTs against TB,
PBMCswere infected withMtbH37Rv andwith the clinical strain
Mtb H3, which in hMDM showed enhanced virulence compared
with other Mtb reference and clinical strains (25). Following
infection with Mtb, cysteamine, or cystamine was added in
infected GLS at day 6 p.i. at the concentrations previously used
in macrophages. At day 12 p.i., the total CFU counts were
evaluated, and some GLS parameters were analyzed. As shown
in Figures 6A–D, treatment with cysteamine and cystamine
resulted in a reduction in the number of GLS per field compared
with untreated GLS, while no differences were observed in the
average surface area of these GLS. Interestingly,Mtb H37Rv load
was significantly reduced in these GLS, confirming the anti-
mycobacterial activity of these two TG2 inhibitors. Infection
of PBMCs with Mtb H3 resulted in fewer GLS with smaller
areas compared with the results obtained with Mtb H37Rv
(Figures 6E–G). Again, cystamine significantly reduced the total
CFU of Mtb H3-infected GLS, while the activity of cysteamine
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FIGURE 6 | Cysteamine and cystamine reduce the fitness of Mtb in an in vitro granuloma model containing human innate and adaptive immune cells. PBMCs
obtained from healthy donors were infected with Mtb H37Rv and Mtb H3 (MOI 1:1) for up to 12 days. Representative images of granuloma-like structure formed in
vitro 10 days after infection with Mtb reference strain H37Rv (A) and H3 clinical strain (E). Magnification, ×40. Granuloma formation was scored for each condition;
the means ± standard deviations of scores representative of three experiments each are given in the images. GLS were treated with different drugs at 3 days
post-infection; the medium was replaced: cystamine (400µM), cysteamine (800µM), and INH at MIC concentration. The measurement of the number of GLS and
area was applied on day 10 p.i., 12 fields per sample were evaluated (B,C for Mtb H37Rv; F,G for Mtb H3), and CFU were determined at 3, 6, and 12 days
post-infection (D) and for clinical strain Mtb H3 (H), arrows represent the beginning of treatments (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001).
was lower compared with the results observed in Mtb H37Rv-
infected GLS (Figure 6H). Taken together, these results indicate
that cysteamine and cystamine reduceMtb growth in the human
ex vivomodel of GLS.
To further assess the potentials of these two TG2 inhibitors as
HDTs for TB, the respective activity of cystamine and cysteamine
was assessed in combination with capreomycin and amikacin
in the GLS model. As shown in Figure 6G, treatment with
cysteamine or cystamine significantly reduced Mtb replication
even more efficiently than the treatment with capreomycin in
GLS, and the combined administration of capreomycin with the
TG2 inhibitors did not provide any addictive effect. Conversely,
the combined administration of amikacin with cystamine or
cysteamine warranted an enhanced restriction of intracellular
Mtb compared with the treatment with any of these drugs
alone. Taken together, these results indicate that cystamine and
cysteamine can synergize with a second-line anti-TB drug as
amikacin, supporting their potential usefulness as HDTs for
TB (Figures 7A,B).
DISCUSSION
Our recent report indicating that genetic and pharmacological
inhibition of TG2 restricts Mtb replication in macrophages (16)
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FIGURE 7 | Synergy effect of cysteamine and cystamine with aminoglycosides in GLS model. Granuloma-like structures obtained from healthy donors were infected
with Mtb H37Rv at MOI 1:1 and were treated with different drugs, at 3 days post-infection as described above, with the addition of co-treatment of cysteamine and
cystamine with amikacin (1µg/ml) and capreomycin (4 ug/ml). CFU were determined at 12 days post-infection (A); *p < 0.05, ***p < 0.005, ****p < 0.001 by one-way
ANOVA with Dunnett’s multiple-comparisons test compared with Mtb H37Rv no treatment. To highlight the inhibition of mycobacterial survival following the addition of
different drugs, we expressed the results as percentage of survival of treated vs. untreated cells in B.
prompted us to investigate the potential usefulness of the TG2
inhibitors cystamine and cysteamine as HDTs against TB. In
this study, using a panel of in vitro experimental assays, we
show that cysteamine and cystamine, two known inhibitors
of TG2, can restrict Mtb replication in macrophages infected
with the Mtb H37Rv reference strain and a panel of clinical
isolates representative of different phylogeographic lineages.
Interestingly, we analyzed the AIPD in THP-1 mRFP-GFP-LC3B
cells infected with Mtb and observed, for the first time, that
cystamine inhibited autophagy while restricting Mtb replication,
confirming our previous observation (16). Overall, the results of
this study support the potential usefulness of the TG2 inhibitors
cysteamine and cystamine as HDTs against TB.
TG2 is known to contribute to a few important pathologies
(15). Among the drugs that inhibit TG2, there are two small
molecules, cystamine and cysteamine. These two drugs are safe
when administered in humans; cysteamine is used to treat
cystinosis (33, 34), and both cysteamine and cystamine have
been used in human clinical trials in the treatment of diseases
which directly or indirectly implicate TG2 and autophagy
deregulation such as Huntington disease (35), cystic fibrosis
(36, 37), and celiac disease (38). It is noteworthy that cystamine
has been used as a support treatment in cancer therapy (39).
In keeping with the data reported in this study, TG2 and
autophagy are both up-regulated in cancer, playing a crucial
role in oncogenesis (39, 40). Thus, the inhibitory action exerted
by cysteamine and cystamine both on autophagy and TG2
could represent an efficient approach to favor the sensitization
of cancer cells to chemo/radio/immune therapy. Our results
showing that cysteamine and cystamine have an anti-TB activity
when administered in a monocyte-derived macrophage cell line,
in primary macrophages, or PBMCs infected with Mtb suggest
that these drugs can be safely used as HDTs for TB (9).
Cystamine and cysteamine are reducing agents that can
affect cell metabolism by increasing glutathione and L-cysteine
level (35, 41). Recently, it has been demonstrated that L-
cysteine or NAC can promote respiration in axenic Mtb culture,
preventing the emergence of drug tolerance against the two
most powerful anti-TB drugs, isoniazid and rifampicin (20).
In these experiments, L-cysteine or NAC where administered
at a concentration of 4mM, which is five times higher
than the concentration we used in our experiments involving
Mtb-infected macrophages. Indeed NAC administered at a
concentration of 10mM was shown to directly decrease Mtb
replication (42). However, in this study, we show a reproduction
of the experimental conditions indicated in Vilcheze et al.
(20), wherein cystamine or cysteamine, when administered
at the concentrations used in Mtb-infected macrophages (400
and 800µM, respectively), did not exert any direct activity
against Mtb cultured in axenic media and did not prevent the
emergence of drug tolerance against isoniazid. It follows that
the anti-tuberculosis activity of cysteamine and cystamine that
we observed in THP-1 monocyte-derived macrophages, primary
macrophages, and PBMCs is not the result of a direct effect
on Mtb. Moreover, Vilcheze et al. (20) showed that only the
molecules with a free thiol group (as L-cysteine and NAC) may
enhance Mtb metabolism, while the oxidized form, as cystine,
does not exert any activity. Conversely, in our experiments, both
cysteamine and cystamine similarly inhibit Mtb intracellularly
in infected macrophages. This suggests that the mechanism of
the anti-TB activity of the two anti-TG2 drugs described in the
present study is different from that observed when L-cysteine
or NAC is administered at a much higher concentration in Mtb
axenic cultures.
It remains to be elucidated how the impairment of autophagy
homeostasis by cysteamine and cystamine may contribute to
restrict Mtb replication. It is well-established that induction
of autophagy by various stimuli, such as rapamycin, IFN-
γ, and Vitamin D3, promotes the lysosomal degradation of
Mtb (43). However, the role of basal autophagy in infected
macrophages appears to be more complex. We have recently
demonstrated that Mtb strains from ancient and modern
lineages have a different impact on the basal autophagy flux
(25). While the ancient lineages impair the autophagic flux,
infection with the modern strains leads to a stimulation of this
process, which is dependent on the increased production of
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IL1-β triggered by these mycobacteria (25). This induction of
autophagy is however ineffective in restricting Mtb growth but
rather correlates with more exuberant Mtb replication, perhaps
by sustaining its metabolic requirements in the infected cells
(25, 44). These observations lend support to the hypothesis
that a blanket inhibition of the autophagic flux in Mtb-infected
macrophages may be detrimental for Mtb, perhaps because
it would activate apoptosis, and that Mtb may manipulate
this process in a more complex and dynamic way (45, 46).
Autophagy is a complex and conserved process that involves
multiple autophagy-associated enzymes; yet, apart from Atg5,
autophagy-deficient mice do not show increased susceptibility
to Mtb infection (47). Interestingly, the dramatic difference
in the inflammatory response was the predominant driver
for the enhanced susceptibility to Mtb infection in ATG5-
deficient mice (47), highlighting the remarkable consequences
that disruption of autophagic homeostasis can have during Mtb
infection. These experimental observations suggest that Mtb has
developed multiple strategies to escape autophagy engulfment
and regulate the autophagy flux to fine-tune its pathogenetic
strategies. Based also on the evidences generated in this study,
we propose that impairment of the autophagic flux by the TG2
inhibitors is detrimental for Mtb intracellular growth. Further
experiments are required to elucidate the functional link between
impairment of autophagy homeostasis and Mtb growth and
its consequences on inflammation when cells are treated with
cysteamine and cystamine.
Mycobacterium tuberculosis complex (MTBC) is a genetically
monomorphic species which evolved by clonal expansion since
more than 100,000 years ago, leading to seven phylogeographic
lineages which show different pathogenetic and virulence
properties (27, 28). Most of the human TB cases at global level
are caused by Mtb strains belonging to the modern lineages L2,
L3, and L4, which seem to show enhanced pathogenic properties
(29, 48, 49). More recent evidences indicate that even within
these modern lineages, some clades or clusters may be more
successful or virulent than others, indicating that the relative little
genetic variability within Mtb can nevertheless have significant
impact on infection outcome (28, 49). We and others have
recently shown that Mtb strains of diverse lineages and clades
can differently manipulate the autophagic process in infected
macrophages, with consequences in terms of intracellular
survival and cytokine/chemokine secretion (25, 50, 51). In this
study, we show that the inhibition of TG2 by cysteamine or
cystamine can effectively inhibit intracellular Mtb regardless
of MTBC lineage. Indeed Mtb strains of the H3 and Beijing
clade, which are characterized by an enhanced in vitro virulence
compared to the other lineages (25), were inhibited by the anti-
TG2 drugs, although at a lower level compared with the results
observed with the other Mtb strains. Since Mtb H3 was shown
to modulate the autophagy flux differently compared to the
other Mtb strains, exploiting the autophagic process for its own
survival (25), it is possible that the anti-TG2 drugs cysteamine
and cystamine are less effective in inhibiting the intracellular
Mtb H3. Nonetheless, these results demonstrate that cysteamine
and cystamine have an antibacterial activity against several Mtb
clinical strains representative of the global diversity ofMTBC and
support the finding that these anti-TG2 molecules are acting as
HDTs by boosting macrophage antimicrobial responses.
Inhibition of TG2 and the ensuing effect on autophagy,
in addition with the capability of these drugs to increase
the generation of glutathione-S-transferase (52), may have
consequences on the pattern of chemokines and cytokines
secreted by infected macrophages. To evaluate the activity of
cystamine and cysteamine in a more complex system, involving
multiple cell types, we implemented the ex vivo model of GLS
(31, 53). Treatment with cystamine or cysteamine of PBMCs
infected with theMtbH37Rv reference strain and theMtb clinical
strain H3 indicates a significant reduction in the total bacterial
burden in GLS, although no major differences in GLS size were
observed. These results indicate that the two anti-TG2 molecules
can exert their anti-TB activity even in this ex vivo model of
infection, further supporting their role as HDTs for TB.
HDTs against TB shall ideally serve to improve and eventually
shorten current anti-TB regimens during treatment of drug-
susceptible TB and, most importantly, drug-resistant TB. In fact,
regimens against MDR-TB are longer and more toxic primarily
because second-line drugs show reduced antimicrobial activity
compared to isoniazid and rifampicin. Since the success rate for
drug-susceptible TB is around 95% (54), we anticipate that any
HDTs against TB will be tested and the activity will be measured
inMDR-TB patients receiving second-line drugs. It is remarkable
that cysteamine, and more robustly cystamine, can reduce
intracellular Mtb growth similarly to the two aminoglycosides
tested, underscoring on one side the potential antimicrobial
activity of these two molecules and on the other the poor
activity of the second-line drugs. Given the important potential
clinical implications, we investigated the synergistic activity of
the two anti-TG2 molecules with second-line drugs as those
of the aminoglycoside class. The finding that cysteamine and
cystamine synergized when administered in combination with
capreomycin and most importantly with amikacin in primary
human macrophages infected with Mtb and in the GLS ex vivo
model of infection further highlights the potential usefulness of
these two anti-TG2 inhibitors as HDTs against TB.
In conclusion, this study shows for the first time that
cystamine and cysteamine display anti-Mtb activity while
inhibiting host cell autophagy. These safe FDA-approved
drugs have high potential applications against Mtb infection
in combination with canonical anti-TB regimen to improve
and shorten regimens against drug-susceptible TB and most
importantly during treatment of MDR-TB patients or of patients
which are at higher risk of non-compliance as migrants or
homeless. In the future, specifically designed clinical trials should
validate the efficacy for their utilization in the clinical practice,
opening a new avenue in the treatment of TB.
MATERIALS AND METHODS
Reagents and Bacterial Strains
The M. tuberculosis strain H37Rv, Mtb complex clinical strains
(MTBC), and M. bovis BCG were isolated at the Fondazione
Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore
(25, 55). The strains were grown in Middlebrook 7H9 (Difco,
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Sparks, MD) supplemented with 10% (vol/vol) oleic acid-
albumin-dextrose-catalase (OADC; Difco), with 0.2% glycerol
(Microbiol, Cagliari, Italy) and 0.05% Tween 80 (Sigma-Aldrich,
St. Louis, MO) at 37◦C. Mycobacterial cultures were harvested at
late log phase, glycerol was added at 20% final concentration, and
1-ml aliquots stored at −80◦C. All experiments with Mtb strains
were carried out in biosafety laboratory level 3 (BSL-3), following
standard safety procedures.
Growth of Mtb in vitro Cultures
Mtb H37Rv cultures were diluted until a final concentration of
≈107 CFU/ml, treated with the appropriate chemicals (cystamine
400µM, cysteamine 800µM, NAC 4mM, INH 7.3µM, or
the combination INH/Cystamine, INH/cysteamine, INH/NAC
using the same concentrations as the individual treatment),
AND incubated at 37◦C with shaking for the duration of the
experiment, and CFU were obtained by plating serial dilutions.
Plates were incubated at 37◦C for up to 6 weeks. All experiments
were carried out in BSL-3.
Study Participants
The PBMCs were derived from healthy donors. Participants were
recruited among people who had recently tested negative for QFT
negative, not vaccinated with BCG, male, Caucasian, and aged
between 30 and 35 years. Written informed consent was obtained
from each donor.
Cell Cultures
Human THP-1 cells wt were stably transduced with a retroviral
vector encoding GFP-RFP-LC3 (56). Wt and transgenic THP-1
were grown in RPMI 1640 supplemented with glutamine (2mM)
and 10% FBS. Cells were treated with 20 nM PMA (Sigma-
Aldrich, St. Louis, MO) for 24 h to induce their differentiation
into macrophages, then washed three times with PBS, and
maintained in 5% FCS.
Peripheral blood mononuclear cells (PBMCs) were obtained
from healthy donors. PBMCs were isolated by density gradient
centrifugation. Monocytes were purified from PBMCs by positive
sorting, using anti-CD14–conjugated magnetic microbeads
(Miltenyi Biotec, Auburn, CA). Human monocyte-derived
macrophages (hMDM) were obtained by cultivating adherent
monocytes for 5–6 days in X-Vivo 15 medium (Lonza,
Walkersville, MD), 2% human serum (Euroclone, Paignton,
United Kingdom) at 37◦C in a 5% humidified atmosphere until
macrophage differentiation (25).
Human cells were infected with different strains of MTBC
[multiplicity of infection (MOI) 1: 1], and at various time-points
(4 h, 2 and 7 days for hMDM), cells were washed twice with sterile
phosphate-buffered saline (PBS) to remove extracellular bacteria,
lysed in 0.01% Triton-X100 (Sigma-Aldrich, St. Louis, MO) and
intracellular bacterial loads (in CFU) determined as previously
described (57).
To assess the synergistic effect of cystamine and cysteamine
with standard antibacterial drugs, we added 4 h and 3 days
post-infection, respectively for hMDM instead of hMMO
and GLS, capreomycin (4µg/ml) (Sigma-Aldrich, St. Louis,
MO), amikacin (1µg/ml) (Sigma-Aldrich, St. Louis, MO) and
combination of these drugs with cystamine and cysteamine.
Granuloma-Like Structure Formation and
Quantification
PBMCs were obtained from healthy donors and isolated as
described above. PBMCs (containing∼1× 105 monocytes) were
immediately infected withMtb at a MOI of 1:1 and incubated for
up to 10–12 days, during which time granuloma was developed
and analyzed (31, 58). The analysis of stage of GLS has been
done daily by using an inverted light microscope. At least
12 separate fields per sample were used to establish the area
and total number of GLS (31). Intracellular bacterial growth
was assessed by counting the CFU; infected GLS were lysed
at different time-points (3, 6, and 12 days post-infection) as
described previously (57).
Confocal Microscopy
Images were obtained by using an inverted confocal microscope;
the slides were then placed on the inverted confocal microscope
(Nikon A1 MP) equipped with an on-stage incubator (T =
37◦C, 5% CO2, OKOLAB), and 32 channel spectral images
were obtained using a ×60 objective (NA 1.4) under 488-
nm excitation for Nile Red. Internal photon multiplier tubes
collected images in 16-bit, unsigned images at 0.25ms dwell
time. mRFP-GFP-LC3 was excited by an argon-ion laser line
(excitation wavelength, 488 nm; emission ranges, 500–550, 570–
620 nm). DsRED fluorescence was monitored in the channel
500–550 nm. Photomultiplier tube gain values were kept fixed
during the experiment. Pinhole was set to 1A.U.Z-. Analysis
of images acquired was performed with ImageJ 1.41 (NIH).
AIPD determination was obtained following Maulucci et al.
(21). Briefly, the R index was obtained by calculating the ratio
between fluorescence emissions in the 500–550 nm (FG) and
570–620 nm (FR) ranges, upon sample excitation at 488 nm. By
mapping R over the entire microscope scanning field, R images
can be created with the homemade downloadable software Redox
Maps Generator Green (59), and red images were overlaid;
maxima of red and green channels, representing autophagy
intermediates (“puncta”), were retrieved by the FIND MAXIMA
plugin (ImageJ). Regions of interests, including whole organelles,
were manually drawn in correspondence of the maxima, and
fluorescence intensity values were measured directly on the R
image through the SYNC WINDOWS plug-in (ImageJ). Puncta
without detectable EGFP fluorescence wereminimized to<5% of
the total number by setting adequate values for photomultipliers.
At least 50 cells per sample were analyzed to build the histogram.
Fluorescence intensities and intensity ratio data were presented
as mean ± SD, and differences were assessed by using χ2-test.
Values of p < 0.05 were considered as significant.
Statistics
Data were analyzed using the GraphPad Prism software, version
7.02 for Windows (GraphPad Software, San Diego, CA). All
experiments were performed at least three times in triplicate.
Growth of Mtb H37Rv in in vitro cultures was evaluated
using one-way ANOVA with Dunnett’s multiple-comparisons
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test against Mtb H37Rv untreated; the statistical significance of
the differences between MTBC strains was evaluated using two-
way ANOVA with Dunnett’s multiple-comparisons test against
each strain with untreated condition. The healthy donors used
for GLS formation were adult (18–45 years of age), uninfected,
and non-vaccinated. Differences were considered significant if
p-values were ≤0.05.
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